5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide
C20H20ClN5O2 — CID 146110603
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide
5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide (PubChem CID 146110603) has the molecular formula C20H20ClN5O2 and a molecular weight of 397.87 g/mol. Its IUPAC name is 5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide.
Molecular Properties
| Compound Name | 5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide |
|---|---|
| PubChem CID | 146110603 |
| Molecular Formula | C20H20ClN5O2 |
| Molecular Weight | 397.87 g/mol |
| Exact Mass | 397.13 |
| IUPAC Name | 5-chloro-N-[(1R,2R)-2-hydroxy-4-[(2-phenylimidazol-1-yl)methyl]cyclopentyl]pyrimidine-4-carboxamide |
| SMILES | O=C(N[C@@H]1CC(Cn2ccnc2-c2ccccc2)C[C@H]1O)c1ncncc1Cl |
| InChI | InChI=1S/C20H20ClN5O2/c21-15-10-22-12-24-18(15)20(28)25-16-8-13(9-17(16)27)11-26-7-6-23-19(26)14-4-2-1-3-5-14/h1-7,10,12-13,16-17,27H,8-9,11H2,(H,25,28)/t13?,16-,17-/m1/s1 |
| InChIKey | LPPJCLHAGLOMAD-SYFTWWQRSA-N |
| XLogP | 2.56 |
| TPSA | 92.93 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 397.87 |
| LogP ≤ 5 | 2.56 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146110603 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.